Drug Profile
T cell gene therapy - Immunomedics
Latest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Immunomedics
- Class Antivirals; Gene therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 16 Jul 2016 No recent reports of development identified for phase-I development in Colorectal-cancer in USA
- 28 Apr 2000 New profile